• Explore /
  • Poster
  • / REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan—Biomarker analysis.

REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan—Biomarker analysis.

Abstract Poster

Authors

null

Yasushi Tsuji

Department of Medical Oncology, Tonan Hospital, Sapporo, Japan

Yasushi Tsuji , Kohei Shitara , Takeharu Yamanaka , Tadamichi Denda , Katsunori Shinozaki , Yoshito Komatsu , Yoshimitsu Kobayashi , Junji Furuse , Hiroyuki Okuda , Masako Asayama , Kohei Akiyoshi , Yoshinori Kagawa , Takeshi Kato , Eiji Oki , Takashi Ando , Yasuhiro Hagiwara , Yasuo Ohashi , Takayuki Yoshino

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

UMIN000011294

Citation

J Clin Oncol 36, 2018 (suppl; abstr 3510)

DOI

10.1200/JCO.2018.36.15_suppl.3510

Abstract #

3510

Poster Bd #

3

Abstract Disclosures

Similar Posters

First Author: Samuel A. Jacobs

First Author: John H. Strickler

First Author: Kohei Shitara

First Author: Kohei Shitara